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Abstract Synthetic peptides with sequences present in extracel- 
lular matrix proteins are capable of causing the expression of the 
inducible form of nitric oxide synthase (iNOS), detected by im- 
munocytochemistry, and the release of NO by human lympho- 
mononuclear cells incubated in their presence. Active peptides are 
15-mers containing a characteristic 2-6-11 motif in which the 
amino acid residue at position 2 is Leu, Ile, Val, Gly, Ala or Lys; 
the residue at position 6 is always Pro; and residue 11 is Glu or 
Asp. The induction of iNOS in human monocytes and macro- 
phages could be involved in the eytotoxicity against tumor cell 
lines also elicited by these peptides. 
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1. Introduction 
The production of nitrate and nitrite by mammalian cells was 
first demonstrated in vitro in mouse peritoneal macrophages in
response to lipopolysaccharide [1]. Later the release of nitric 
oxide (NO) by the same cells was reported [2,3]. It is now well 
established that rodent macrophages possess an inducible nitric 
oxide synthase (iNOS) [4] and also that mouse macrophages 
can be stimulated to release nitric oxide by agents such as 
cytokines, microbial products and tumor cells [5,6]. It is now 
widely accepted that NO synthesized from L-arginine in a reac- 
tion catalyzed by NOS is an antimicrobial and antitumoral 
effector system of mononuclear cells from rodents [7-9]. How- 
ever, it is still controversial whether an analogous ystem is also 
present in human macrophages [10-16]. 
In a previous article [17] we reported that peptides with a 
definite structural pattern (2-6-11 motif) have the ability to 
activate human monocytes and to induce cytotoxicity against 
tumor cell lines when lymphomononuclear cells are incubated 
in the presence of these immunomodulators. These peptides are 
15-mers in which the amino acid residue at position 2 is Leu, 
Ile, Val, Gly, Ala or Lys; the residue at position 6 is always Pro; 
and the residue at position 11 is Glu or Asp. 
The aim of the present study was to examine if the induction 
of iNOS and NO production could be elicited by peptides with 
*Corresponding author. Fax: (34) (48) 105 649. 
Abbreviations: iNOS, inducible nitric oxide synthase; SpA, Staphilococ- 
cus aureus protein A; LPS, lipopolysaccharide; NMMA, N~-mono - 
methyl-L-arginine. 
the pattern conferring immunomodulating activity. The results 
clearly show that peptides derived from Staphylococcus aureus 
protein A (SPA) or from extracellular matrix proteins (ECM) 
were capable of bringing about the induction of NOS and the 
production of NO. 
2. Materials and methods 
2.1. Cell culture 
Lymphomononuclear cells were obtained from peripheral blood of 
healthy donors following the technique described by Boyum [18]. Blood 
lymphomononuclear cells were incubated at 2 x 10 6 per ml in RPMI- 
1640 medium (Biochrom, Berlin, Germany), supplemented with 2.5% 
of autologous erum, 2 mM L-glutamine, penicillin (100 U/ml) and 
streptomycin (100 ,ug/ml) in a 5% CO2 humidified atmosphere. 
2.2. Peptide synthesis 
Peptides were synthesized by the solid phase method of Merrifield 
[19], with the Fmoc modification [20]. 
2.3. Immunocytochemistry 
After incubation cells were pelleted by centrifugation and fixed in a 
formaldehyde-picric mixture [21] for 24 h at 4°C. Cells were then 
washed in 0.1 M phosphate buffer, pH 7.3, resuspended in 6% agarose, 
dehydrated and embedded in paraffin. Cells were sectioned at a thick- 
ness of 5/lm and treated by the avidin-biotinylated peroxidase complex 
technique [22]. After removing the paraffÉn, intrinsic peroxidase was 
blocked by treatment of the sections with a solution of methyl alcohol 
containing 3% H202 for 30 min. Background blocking was performed 
with 1:20 normal pig serum for 30 min prior to incubation with the 
specific primary antiserum, which was carried out for 20 h at 4°C. After 
rinsing with Tris-buffered saline (TBS) (0.05 M Tris, pH 7.36, 0.55 M 
NaC1) the sections were incubated with biotinylated pig anti-rabbit IgG 
(Dakopatts, E353, Glostrup, Denmark) at a 1/200 solution for 30 min. 
Following a second rinsing in TBS, sections were further incubated with 
the avidin-biotinylated complex (1 : 100 Tris dilution, Dakopatts, E355) 
for 30 min. After a final rinsing, peroxidase activity was visualized using 
diaminobenzidine (50 mg per 100 ml) and H202 (10/11 per 50 ml of 
solution). Sections were lightly counterstained with Harris's hematox- 
ylin. A polyclonal rabbit antibody against a 26 amino acid synthetic 
peptide (QNGSPQLLTGTAQNVPESLDKLHVTC) chosen from the 
published sequence of mouse macrophage iNOS [23] was used for the 
present study. The specificity of this antibody for the detection of iNOS 
has been previously shown [24]. Another polyclonal antibody against 
a synthetic fragment (p53) of rat neural NOS [25] was also used for 
some of the control experiments. Both antisera were courtesy of V. 
Riveros-Moreno and S. Moncada (Wellcome Research Labs., Becken- 
ham, Kent, UK). The specificity of the immunoreaction was tested by 
(i) preabsorption of the antiserum with the synthetic antigenic peptide 
(10 nmol/ml of diluted antiserum) and (ii) the use of preimmune serum 
of the same rabbit from which the antibody was obained, diluted 1/20, 
instead of the primary antiserum. 
2.4. Determination f nitrite and nitrate 
When nitrite or nitrate was to be determined, the medium was supple- 
mented with 0.5 mM L-arginine. Cell free supernatants were collected 
after incubation for 48 h and stored at -20°C until analysis. Nitrite 
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concentration i  the medium was quantitated by a colorimetric assay 
based on the Griess reaction [26]. Nitrate concentration was determined 
by a UV method using a commercial kit (Boehringer-Mannheim). 
3. Results 
Peptides elected for this study contained fifteen amino acid 
residues, fourteen of them representing sequences present in 
fibronectin [27], laminin A [28], laminin B1 [29], ~-col lagen IV 
[30] or S. aureus protein A [31]. En extra valine residue was 
always added in the C-terminus for synthesis convenience. 
3.1. Immunocytochemical detection o f  iNOS 
Human lymphomononuclear cells incubated for 7 days in the 
presence of fibronectin or any of the immunomodulating pep- 
tides containing the 2-6-11 motif  (Table 1) were immunoreac- 
tive for iNOS when antiserum against he inducible form of the 
enzyme was used. No immunoreactivity was observed if an 
antibody against he constitutive form of the enzyme was used. 
A clear difference in the number of cells stained with the iNOS 
antiserum can be observed when comparing sections of cells 
incubated with the inactive control peptide Pc (Fig. 1A) with 
those belonging to cells treated with the active peptide P3 
Fig. 1. Inducible nitric oxide synthase in human lymphomononuclear cells demonstrated byimmunocytochemistry. (A) Cells incubated in the presence 
of inactive peptide Pc and stained for iNOS. No immunoreactivity can be observed. (B) Cells incubated in the presence of immunomodulating peptide 
P3 (top), fibronectin (bottom left) or active peptide Pa (bottom right) for 7 days and stained for iNOS. (C) Cells incubated in the presence of active 
peptide P3 for 7 days and stained for iNOS with antiserum previously preabsorbed with the corresponding specific antigen. The absence of 
immunoreactivity confirmed the specificity of the iNOS antiserum used. (D) Adherent cells recovered from lymphomononuclear cells incubated in 
the presence of inactive peptide Pc. No immunoreactivity can be observed. (E and F) Adherent cells, immunoreactive monocytes and macrophages, 
recovered from lymphomononuclear cells incubated in the presence of peptides P3 and Pa, respectively. 
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Table 1 
Nitrite production by human lymphomononuclear cells incubated with immunomodulating peptides 
123 
Addition Peptide sequence a Protein Position b NO2 (nmol/105 cells) 
Medium NMMA 
None 0.80 + 0.3 0.76 + 0.2 
P1 Kr.GVRPSQGGEAPR Fibronectin 1088 1101 4.83 _+ 0.3 1.46 + 0.3 
P2 IKGLKPGVVYEGQL Fibronectin 639-652 4.62 + 0.3 1.36 + 0.2 
P3 IZSCHPVGTDEEPL  Fibronectin 2015 2028 4.26 + 0.4 1.37 + 0.3 
P4 LKERNPEGCS~.CFC Laminin A 475~,88 3.97 + 0.3 1.20 + 0.3 
P5 MLRESPGGMREKGR Laminin A 1981 1993 4.26 + 0.4 1.31 _+ 0.3 
P6 G'rSTGPMKKVDDII Laminin B1 155 168 3.98 + 0.3 1.33 + 0.2 
P7 QALASPGSCLDEFR S t Collagen IV 1569-1582 4.78 + 0.3 1.30 + 0.3 
P8 E'rLMNPNLNEEQR_N SpA 18-31 4.46 + 0.3 1.39 + 0.3 
P9 SLKDDPSVSKEILA  SpA 210-223 4.53 _+ 0.4 1.35 + 0.3 
Pc ADAQQNKFNKDQQS c SpA 1-14 0.76 + 0.3 0.71 + 0.3 
Pa NVLGAPKKLNESQA d 4.84 + 0.3 1.36 + 0.3 
LPS 5.26 + 0.4 1.61 + 0.3 
The results are means _+ S.E.M. for duplicates from one of five similar experiments. Concentration f peptides in the medium was 30 ]./g/106 cells, 
and that of LPS 10 pg/106 cells. When present, NMMA concentration was 1 mM. Incubation time, 48 h. 
" An extra valine residue, not shown, was added to the C-terminus for synthesis convenience. 
b Numbering of the amino acid residues at the corresponding protein. 
c Inactive control peptide. 
J Synthetic non-natural immunomodulating peptide. 
(Fig. 1B, top), fibronectin (Fig. 1B, bottom left) or active pep- 
tide Pa (Fig. 1B, bottom right) under the same conditions. 
Preabsorption of antiserum with the corresponding antigen 
completely abolished immunostaining (Fig. 1C). On a morpho- 
logical basis the vast majority of stained cells could be consid- 
ered as monocytes and macrophages. This point received fur- 
ther support when monocytes, which spontaneously adhered to 
the culture plates during the incubation, were scraped off after 
removing the supernatant containing non-adherent cells. Mon- 
ocytes were then resuspended in a small volume of incubation 
medium and processed as the entire lymphomononuclear pop- 
ulation (Fig. I D F). Adherent cells recovered from lympho- 
mononuclear cells which had been incubated with inactive pep- 
tide Pc showed no immunoreactivity (Fig. 1D). However, mon- 
ocytes and macrophages were clearly immunoreactive if recov- 
ered cells had been incubated in the presence of peptide P3 (Fig. 
IE) or active peptide Pa (Fig. 1F). 
3.2. NO release 
Table 1 shows the accumulation of nitrite in the medium 
when human lymphomononuclear cells were incubated for 
48 h in the presence of active peptides. The production of nitrite 
was very similar to that caused by LPS. No release took place 
when the incubation was carried out in the presence of an 
inactive control peptide, Pc. The release of nitrite was inhibited 
when N~-monomethyl-L-arginine was present in the medium 
during the incubation. Nitrate was also detected in the medium 
when cells were incubated in the presence of active peptides or 
LPS (approximately 1.3 nmol of nitrate/105 cells). The nitrate 
level was lower (0.4 nmol/105 cells) when cells were incubated 
in the absence of peptides or in the presence of the inactive 
peptide Pc. 
4. Discussion 
The production of NO by human monocytes after prolonged 
exposure to GM-CSF and TNF-a  [10], INF-z  and TNF-ct, or 
LPS [11], and an ensuing increase in NO-dependent phagocytic 
activity has been reported. It has also been described that after 
the spontaneous maturation of isolated monocytes to macroph- 
ages, reactive nitrogen intermediates are employed in mediating 
macrophage cytotoxicity [12]. The production of NO by mon- 
ocytes in alcoholic liver disease [13], and the stimulation of NO 
release in vitro by human monocytes, when brought into con- 
tact with tumor cells, has also been reported [14]. More re- 
cently, expression of iNOS mRNA in human monocytes stimu- 
lated with LPS/IFN- Z has been demonstrated [15]. However, 
doubts regarding the release of NO by human monocytes till 
remain, since other workers have been unable to detect prod- 
ucts related to this nitrogen intermediate in cultures of these 
cells with cytokines or LPS [VVI6]. Under our experimental 
conditions, using human lymphomononuclear cells, we have 
detected significant levels of nitrite and nitrate released to the 
medium. An explanation of these discrepancies could be that 
we were using the whole lymphomononuclear population, not 
isolated monocytes; and interactions between these cells and 
lymphocytes might play some role in the translation or activa- 
tion of the enzyme. 
The results now reported clearly demonstrate he expression 
of the inducible form of the enzyme nitric oxide synthase in 
human monocytes and macrophages present in a population of 
lymphomononuclear cells activated by short immunomodu- 
lating peptides. The production of NO seems to indicate that 
the enzyme detected by immnunocytochemistry waspresent in 
its active form. Since peptides with the described 2-6-11 motif 
are also inducers of cytotoxicity against umor cell lines [17,32], 
it may be suggested that this effect could be mediated by the 
NO produced by the activated cells. 
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